Reaction Details |
![](/images/Email.png) | Report a problem with these data |
Target | MAP kinase-interacting serine/threonine-protein kinase 1 |
---|
Ligand | BDBM550559 |
---|
Substrate/Competitor | n/a |
---|
Meas. Tech. | MKNK1 Kinase High ATP Assay |
---|
IC50 | 2.40±n/a nM |
---|
Citation | Klar, U; Bohlmann, R; Schäcke, H; Sülzle, D; Menz, S; Panknin, O Substituted dihydroimidazopyridinediones as MKNK1 and MKNK2 inhibitors US Patent US11311520 Publication Date 4/26/2022 |
---|
More Info.: | Get all data from this article, Assay Method |
---|
|
MAP kinase-interacting serine/threonine-protein kinase 1 |
---|
Name: | MAP kinase-interacting serine/threonine-protein kinase 1 |
Synonyms: | MAP Kinase-Interacting Protein Kinase (MNK1) | MAP kinase signal-integrating kinase 1 | MAP kinase-interacting serine/threonine-protein kinase 1 (MnK1) | MAP kinase-interacting serine/threonine-protein kinase MNK1 | MAP-kinase interacting kinase 1 (MNK1) | MAPK signal-integrating kinase 1 | MKNK1 | MKNK1_HUMAN | MNK1 |
Type: | Serine/threonine-protein kinase |
Mol. Mass.: | 51342.85 |
Organism: | Homo sapiens (Human) |
Description: | Q9BUB5 |
Residue: | 465 |
Sequence: | MVSSQKLEKPIEMGSSEPLPIADGDRRRKKKRRGRATDSLPGKFEDMYKLTSELLGEGAY
AKVQGAVSLQNGKEYAVKIIEKQAGHSRSRVFREVETLYQCQGNKNILELIEFFEDDTRF
YLVFEKLQGGSILAHIQKQKHFNEREASRVVRDVAAALDFLHTKDKVSLCHLGWSAMAPS
GLTAAPTSLGSSDPPTSASQVAGTTGIAHRDLKPENILCESPEKVSPVKICDFDLGSGMK
LNNSCTPITTPELTTPCGSAEYMAPEVVEVFTDQATFYDKRCDLWSLGVVLYIMLSGYPP
FVGHCGADCGWDRGEVCRVCQNKLFESIQEGKYEFPDKDWAHISSEAKDLISKLLVRDAK
QRLSAAQVLQHPWVQGQAPEKGLPTPQVLQRNSSTMDLTLFAAEAIALNRQLSQHEENEL
AEEPEALADGLCSMKLSPPCKSRLARRRALAQAGRGEDRSPPTAL
|
|
|
BDBM550559 |
---|
n/a |
---|
Name | BDBM550559 |
Synonyms: | N-{4-[(8′-Methyl-1′,5′-dioxo-1′,5′-dihydro-2′H-spiro[cyclopentane-1,3′-imidazo[1,5-a]pyridin]-6′-yl)amino]-1,3,5-triazin-2-yl}cyclopropanecarboxamide | US11311520, Example 53 |
Type | Small organic molecule |
Emp. Form. | C19H21N7O3 |
Mol. Mass. | 395.4151 |
SMILES | Cc1cc(Nc2ncnc(NC(=O)C3CC3)n2)c(=O)n2c1C(=O)NC21CCCC1 |
Structure |
|